Phase I study of vinorelbine and carboplatin in advanced non-small cell lung cancer (Q72012069)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7655834%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

title

Phase I study of vinorelbine and carboplatin in advanced non-small cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7655834%20AND%20SRC:MED&resulttype=core&format=json

non-small-cell lung carcinoma

22 October 2019

main subject

1 reference

1 reference

P. Jacoulet

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7655834

22 July 2024

J. L. Breton

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7655834

22 July 2024

V. Westeel

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7655834

22 July 2024

M. Mercier

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7655834

22 July 2024

G. Garnier

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7655834

22 July 2024

A. Depierre

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7655834

22 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=7655834

22 July 2024

publication date

1 June 1995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7655834%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

22 October 2019

https://api.elsevier.com/content/article/PII:016950029500448A?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

https://api.elsevier.com/content/article/PII:016950029500448A?httpAccept=text/plain

22 July 2024

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

22 July 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7655834%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7655834%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7655834%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

page(s)

247-257

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7655834%20AND%20SRC:MED&resulttype=core&format=json

Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience

22 October 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

Phase I-II study of vinorelbine (Navelbine) plus cisplatin in advanced non-small cell lung cancer

22 July 2024

2

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group

22 July 2024

4

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

22 July 2024

6

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group

22 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

A Phase II Study of Navelbine (Vinorelbine) in the Treatment of Non-Small-Cell Lung Cancer

22 July 2024

9

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial

22 July 2024

10

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer

22 July 2024

11

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

A phase II trial of carboplatin (CBDCA) in small-cell and non-small-cell lung cancer with correlation to in vitro analysis of cytotoxicity

22 July 2024

12

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer

22 July 2024

13

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: A randomized study

22 July 2024

14

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

The calculation of received dose intensity

22 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium

22 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.

22 July 2024

20

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

Randomized phase II evaluation of iproplatin (CHIP) and carboplatin (CBDCA) in lung cancer. A Southeastern Cancer Study Group trial.

22 July 2024

21

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30-minute infusion

22 July 2024

22

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

Carboplatin or iproplatin in advanced non-small cell lung cancer: a Cancer and Leukemia Group B Study

22 July 2024

23

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

22 July 2024

24

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

Phase II trial of carboplatin in non-small cell lung cancer

22 July 2024

27

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents

22 July 2024

28

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer. Results of a prospective randomized FONICAP trial. Italian Lung Cancer Task Force

22 July 2024

29

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

Chemotherapy for adenocarcinoma of the lung (WHO III): A randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs

22 July 2024

30

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

Polychemotherapy in advanced non small cell lung cancer: a meta-analysis

22 July 2024

31

1 reference

https://api.crossref.org/works/10.1016/0169-5002(95)00448-A

22 July 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7655834%20AND%20SRC:MED&resulttype=core&format=json

22 October 2019

1 reference